Raczyńska Krystyna, Gebka Andrzej, Iwaszkiewicz-Bilikiewicz Barbara, Ciechanowski Cezary
Katedry i Kliniki Chorób Oczu Akademii Medycznej w Gdańsku.
Klin Oczna. 2004;106(3 Suppl):481-4.
The vitreoretinal re-proliferations (PVR) are the most eminent cause of retinal surgery misfortunes. Daunorubicin has been widely discussed as the antimetabolic drug for PVR treatment for recent 20 years. The aim of the study was to evaluate the usefulness of daunorubicin, applied intravitreally during vitrectomy, as an antiproliferative factor stopping the vitreoretinal re-proliferations in eyes with rhegamatogenous retinal detachment complicated with PVR.
Vitrectomy, with daunorubicin infusion (1 microg/ml), was performed in 6 eyes with rhegamatogenous retinal detachment and PVR. In 6 other cases of retinal detachment, the gentamycine (20 mg/ml) solution was used as a vitrectomy infusion. During the 12 months follow-up, the risk of PVR relapse was evaluated.
There was no signs of PVR relapse in the eyes treated with daunorubicin during the 12 months follow-up. As in the group of patients that had no daunorubicin infusion the PVR re-proliferation occurred in 2 of 6 operated eyes.
12 months follow-up showed that Daunorubicine could be a useful adjuvant drug reducing the rate of re-proliferations in the patients with rhegamatogenous retinal detachment.
玻璃体视网膜再增殖（PVR）是视网膜手术失败的最主要原因。近20年来，柔红霉素作为治疗PVR的抗代谢药物已被广泛讨论。本研究的目的是评估在玻璃体切除术中玻璃体腔内应用柔红霉素作为抗增殖因子，对孔源性视网膜脱离合并PVR患者阻止玻璃体视网膜再增殖的有效性。
对6例孔源性视网膜脱离合并PVR的患者实施玻璃体切除术，并注入柔红霉素（1微克/毫升）。另外6例视网膜脱离患者，使用庆大霉素（20毫克/毫升）溶液作为玻璃体切除术中的灌注液。在12个月的随访期间，评估PVR复发的风险。
在12个月的随访期间，接受柔红霉素治疗的患者眼中没有PVR复发的迹象。而在未注入柔红霉素的患者组中，6例手术眼中有2例发生了PVR再增殖。
12个月的随访表明，柔红霉素可能是一种有用的辅助药物，可降低孔源性视网膜脱离患者的再增殖率。
